Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD)

Historical Holders from Q1 2025 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.00001 per share (the "Shares")
Symbol
AARD on Nasdaq
Shares outstanding
21,303,054
Price per share
$13.29
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
9,465,972
Holdings value
$125,803,412
% of all portfolios
0%
Share change
+529,150
Value change
+$6,848,422
Average buys %
+0%
Average sells %
-0%
Number of holders
48
Price from insider filings
$14.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lee Tien-Li 14% $34,103,965 2,983,724 Tien-Li Lee 31 Mar 2025
Tan Finian 9.6% $23,441,810 2,050,902 Vickers Venture Fund VI Pte. Ltd. 12 Feb 2025
CITADEL ADVISORS LLC 5.6% $13,635,659 1,192,971 Kenneth Griffin 14 Feb 2025
As of 30 Sep 2025, Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) has 48 institutional shareholders filing 13F forms. They hold 9,465,972 shares of 21,303,054 outstanding shares (44%) .

Top 25 institutional shareholders own 44% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Decheng Capital LLC 18% 3,917,299 0% 9.1% $52,060,903
CITADEL ADVISORS LLC 6.4% 1,359,883 +5.9% 0.01% $18,072,846
Laurion Capital Management LP 4.9% 1,049,721 +6.1% 1.9% $13,950,792
VANGUARD GROUP INC 2.6% 555,721 +21% 0% $7,385,532
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.6% 350,000 +100% 0.01% $4,651,500
MILLENNIUM MANAGEMENT LLC 1.5% 319,623 0% $4,247,790
BlackRock, Inc. 1.5% 309,465 +50% 0% $4,112,790
SILVERARC CAPITAL MANAGEMENT, LLC 1.4% 306,912 +7% 0.59% $4,078,861
Schonfeld Strategic Advisors LLC 1.2% 253,752 -9.1% 0.02% $3,372,361
GEODE CAPITAL MANAGEMENT, LLC 0.91% 194,035 +42% 0% $2,578,990
Cresset Asset Management, LLC 0.69% 146,783 0.01% $1,950,746
CANTOR FITZGERALD, L. P. 0.45% 96,682 +26% 0.03% $1,284,904
STATE STREET CORP 0.44% 93,005 +149% 0% $1,236,036
MORGAN STANLEY 0.32% 68,462 +664% 0% $909,860
TWO SIGMA INVESTMENTS, LP 0.3% 63,569 0% $844,832
NORTHERN TRUST CORP 0.27% 57,197 +27% 0% $760,149
BNP PARIBAS FINANCIAL MARKETS 0.27% 56,546 0% 0% $751,496
UBS Group AG 0.26% 54,728 +5.4% 0% $727,335
BARCLAYS PLC 0.19% 39,926 -21% 0% $530,617
TWO SIGMA ADVISERS, LP 0.12% 25,700 0% $341,553
BANK OF AMERICA CORP /DE/ 0.11% 23,930 +200% 0% $318,031
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.1% 22,000 0.01% $292,380
JANE STREET GROUP, LLC 0.09% 19,447 0% $258,451
GOLDMAN SACHS GROUP INC 0.09% 18,927 +1.8% 0% $251,540
Bank of New York Mellon Corp 0.07% 15,523 0% $206,301

Institutional Holders of Aardvark Therapeutics, Inc. - Common Stock, par value $0.00001 per share (the "Shares") (AARD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 9,465,972 $125,803,412 +$6,848,422 $13.29 48
2025 Q2 8,915,770 $120,541,916 +$8,913,830 $13.52 35
2025 Q1 8,686,452 $65,110,057 +$64,849,535 $7.51 27